Skip to content
DataLookout
Menu

CLSABNCT07880860

Cleft Lip Scarring After Botox

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified
    • Secondary endpoint revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Scar Quality Measured by the Vancouver Scar Scale Total Score
Timeframe: 1 month, 3 months, 6 months, and 12 months postoperatively
Parent-Reported Scar Appearance Measured by the Visual Analog Scale
Timeframe: 1 month, 3 months, 6 months, and 12 months postoperatively
Scar Width Measured on Standardized Photographs (mm)
Timeframe: 1 month, 3 months, 6 months, and 12 months postoperatively

Secondary (1)

Incidence and Severity of Botulinum Toxin Type A-Related Adverse Events Assessed by Clinical Evaluation

Arms and interventions

Botulinum Toxin Type AExperimental

Participants undergoing cleft lip repair receive intraoperative botulinum toxin type A injections at the time of surgical repair. Scar outcomes and adverse events are assessed during postoperative follow-up.

PlaceboPlacebo comparator

Participants undergoing cleft lip repair receive intraoperative placebo (normal saline) injections at the time of surgical repair. Scar outcomes and adverse events are assessed during postoperative follow-up.

Drugs: Botulinum Toxin Type A (BOTOX) Injection, Normal Saline

Sites

1 site in 1 country

  • Children's National HospitalWashington D.C., District of Columbia, United States